The Australian Therapeutic Goods Administration (TGA) has approved Lombard Medical’s Aorfix endovascular stent graft for inclusion on the Australian Register of Therapeutic Goods. The TGA has approved the use of Aorfix for the treatment of abdominal aortic aneurysms (AAAs) with aortic neck angulations up to 90 degrees.
“Achieving approval to begin commercial sales of Aorfix in Australia is another important milestone for our company,” said chief executive officer Simon Hubbert. “Product shipments will begin immediately as we work with leading endovascular physicians to bring Aorfix to market in this country.”
